NEW YORK and CLEVELAND, May 08, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ: ABEO ), a fully-integrated leader in gene and cell therapy, today announced that long-term follow up data from a completed Phase 1/2 study evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) will be presented at the 77 th Annual Meeting of the Society for Investigative Dermatology (SID), being held May 8-11 in Chicago. The data will be presented by Stanford University researcher Shaundra Eichstadt, M.D. in two forums at the meeting, as detailed below. As previously reported, these data showed that three years after treatment with EB-101, a majority of RDEB patients had durable wound healing. Notable improvements were also reported in outcomes associated with wound healing, including patient reported reductions in pain and itching. No serious treatment-related adverse events were observed at three years, and no replication competent virus was present at any time point....
Read more
